Acute myeloid leukemia in HIV-positive patients: biological crossroads and therapeutic Hurdles Authors: Mohamed J Saadh, Faris Anad Muhammad, Rafid Jihad Albadr, Vimal Arora, Subbulakshmi Ganesan, Aman Shankhyan, Ajay Sharma, Jasur Rizaev, Waam Mohammed Taher, Mariem Alwan, Mahmood Jasem Jawad, Ali M Ali Al-Nuaimi Published: 2026 ABSTRACT AbstractAcute myeloid leukemia (AML), characterized by aberrant hematopoiesis and aggressive clinical behavior, remains a therapeutic challenge even with advances in targeted therapies and hematopoietic stem cell transplantation. In human immunodeficiency virus (HIV)-infected individuals, leukemogenesis may be accelerated through mechanisms such as chronic inflammation, oxidative stress, and bone marrow microenvironment dysregulation. Conversely, AML-associated immunosuppression can exacerbate HIV pathogenesis, increasing the risk of opportunistic infections and complicating disease management. The overlapping clinical presentations of AML and HIV, including cytopenias and recurrent infections, often obscure diagnosis and complicate treatment decisions. While intensive chemotherapy remains the mainstay of AML treatment, HIV-positive patients face unique challenges, including potential drug-drug interactions and compounded toxicities from concurrent antiretroviral therapy (ART) and chemotherapeutic regimens. This review aims to elucidate the bidirectional relationship between HIV and AML, focusing on relevant epidemiological data, underlying molecular mechanisms, and distinct clinical features. More importantly, it identifies critical knowledge gaps that must be addressed to optimize diagnostic and therapeutic approaches for the high-risk population.Keywords: Acute myeloid leukemia, human immunodeficiency virus, Immunodeficiency, Leukemia, Antiretroviral Therapy Introduction The human immunodeficiency virus (HIV) remains a major global health challenge, with an estimated 40.8 million people affected at the end of 2024 [1]. By targeting CD4 + T lymphocytes—central regulators of adaptive immunity—HIV causes progressive immunodeficiency and increases susceptibility to opportunistic infections and malignancies [2]. Although antiretroviral therapy (ART) has transformed HIV into a manageable chronic condition, persistent immune activation and inflammation remain hallmark features of treated HIV infection, contributing to accelerated aging and a higher prevalence of non-acquired immunodeficiency syndrome (AIDS)-defining comorbidities, including hematologic malignancies [3]. Acute myeloid leukemia (AML) is a clonal malignancy of myeloid progenitors marked by uncontrolled proliferation and impaired differentiation, leading to cytopenias such as anemia, neutropenia, and thrombocytopenia, with symptoms of fatigue, infection, and bleeding [4]. Globally, AML accounts for 1–2% of all cancer cases, with an annual incidence of approximately 3–5 cases per 100,000 individuals, increasing with age [5]. Furthermore, AML arises from cumulative molecular alterations—including FLT3, NPM1, and TP53 mutations—that drive malignant transformation [6]. Despite advances in targeted therapies and hematopoietic stem cell transplantation (HSCT), overall prognosis remains poor [7]. In this context, the relationship between AML and HIV remains controversial and poorly understood. Epidemiological evidence indicates a slightly elevated risk of AML among HIV-positive individuals, with some studies reporting 2- to 2.5-fold higher leukemia rates compared to HIV-negative populations [8]. HIV-associated immune dysregulation may promote AML development by weakening immune surveillance and creating a pro-inflammatory bone marrow environment that favors leukemic transformation [9, 10]. Additionally, chronic HIV infection and ART may also alter the biological behavior of AML, including its response to therapy [11]. Conversely, AML, as a disease process primarily involving bone marrow and systemic immunity, may potentiate HIV-related immunosuppression, further compromising infection control and increasing vulnerability to opportunistic pathogens. This review examines the bidirectional interplay between HIV and AML, exploring how HIV may modulate AML pathogenesis, disease progression, and treatment efficacy, as well as how AML impacts HIV management and immune reconstitution. By synthesizing existing evidence, we aim to address critical gaps in current understanding and highlight the clinical and biological challenges posed by these coexisting conditions. Elucidating the interactions between HIV and AML is essential for developing tailored therapeutic approaches to improve outcomes in this vulnerable patient population. Search strategy A comprehensive literature search was conducted to identify relevant studies addressing the intersection between HIV infection and AML, using combinations of the following keywords: “HIV,” “AIDS,” “AML,” “acute myeloid leukemia,” “hematologic malignancies,” “immune dysfunction,” “leukemogenesis,” “ART,” and “pathogenesis.” Publications were selected based on their relevance to epidemiological data, molecular mechanisms, clinical features, and therapeutic aspects of AML in HIV-positive individuals. Both research articles and reviews were considered. Reference lists of key articles were also screened to capture additional sources. The findings were synthesized narratively, emphasizing mechanistic insights and clinical implications. Epidemiology and incidence of AML in HIV-Positive patients AML is a relatively rare hematologic malignancy, and its infrequent occurrence, coupled with limited large-scale data on HIV-positive populations, poses significant challenges in establishing definitive conclusions regarding its epidemiology in this group. Current evidence suggests that AML occurs at a modestly increased frequency among HIV-infected individuals, though it remains a relatively rare complication. Studies from the United States and France have reported approximately 2- to 2.5-fold higher rates of leukemia in HIV-positive populations compared with HIV-negative individuals. Similarly, data from Japan estimated an AML incidence of 8 per 100,000 person per year between 1991 and 2009. More recent multicenter analyses suggest that while the overall incidence of acute leukemia in HIV-positive people may not differ significantly from the general population, disease onset tends to occur at a younger age (mean 50 years for AML) [8]. Some studies have suggested that younger individuals living with HIV who develop myelodysplastic syndromes (MDS) may be at an elevated risk of progressing to AML. These individuals also tend to experience lower overall survival rates compared to their HIV-negative counterparts [12, 13]. However, the age range of HIV-positive individuals diagnosed with AML spans broadly from 7 to 70 years, with a median age of approximately 40 years at diagnosis [14, 15]. Epidemiological studies across different regions support a nuanced understanding. A study conducted in Ethiopia by Alemu et al. found that the prevalence of HIV among acute leukemia patients mirrored the national HIV prevalence, a finding echoed by Hagiwara et al. in Japan [15, 16]. In Iran, a retrospective study spanning 2004 to 2017 identified only one case of AML among 39 HIV-positive individuals with cancer, representing an incidence rate of 0.08% [17]. It is well-established that HIV-positive individuals are at heightened risk for various infections and malignancies, including Kaposi’s sarcoma, invasive cervical carcinoma, lymphoma, and potentially AML. This increased vulnerability is largely attributed to HIV’s impact on the immune system, which compromises the body’s ability to mount effective defenses against neoplastic processes [18–20]. Despite these findings, the true incidence and risk of AML among HIV-positive individuals remain elusive due to inconsistent and often contradictory epidemiological data. The rarity of AML, combined with limited representation of HIV-positive patients in large-scale studies, complicates efforts to accurately determine incidence rates. Additional confounders include regional disparities in healthcare access, underreporting in low-resource settings, and the potential influence of ART-related toxicities. While some studies point to persistent immune stimulation and ART as possible risk factors for AML, others find no significant difference from the general population. These inconsistencies underscore the urgent need for well-designed, prospective, multicenter studies that account for demographic diversity, ART regimens, and comorbidities. Such research is essential to clarify the epidemiological relationship between HIV and AML and to inform tailored diagnostic and therapeutic approaches. HIV-induced immune dysfunction and pathophysiological links to acute myeloid leukemia HIV infection induces progressive depletion of CD4 + T lymphocytes, a critical component of adaptive immunity, leading to systemic immune dysfunction through multiple mechanisms, including direct viral cytopathic effects, pyroptosis, syncytia formation, and apoptosis [2]. The gut-associated lymphoid tissue (GALT) is a major site of early HIV replication and undergoes rapid and extensive CD4 + T-cell loss, impairing mucosal integrity and increasing microbial translocation, which perpetuates systemic immune activation and inflammation [21]. Despite effective ART, immune reconstitution is often incomplete, leaving patients with persistently low CD4 + counts and ongoing immune dysregulation. The chronic immune activation characteristic of HIV infection arises from persistent viral replication, opportunistic co-infections, and microbial translocation across compromised mucosal barriers. This persistent activation elevates pro-inflammatory cytokines such as IL-6, TNF-α, and IFN-γ, which remain high even in patients receiving ART. The ongoing immune impairment creates favorable conditions for oncogenic viral co-infections, particularly with Epstein-Barr virus (EBV) and human herpesvirus-8 (HHV-8), further compounding the risk of malignant transformation [22, 23]. HIV can also infect monocytes and macrophages [24]. This infection enhances the DNA-binding activity of the transcription factor NF-κB, which upregulates expression of pro-leukemogenic cytokines like IL-6, G-CSF, and GM-CSF—cytokines that may drive leukemogenesis through both autocrine and paracrine mechanisms [25]. Persistent immune stimulation drives oxidative stress and DNA damage, promoting genomic instability. It also expands myeloid-derived suppressor cells (MDSCs) that suppress antitumor immunity and support oncogenesis [26]. The cumulative result is a chronically activated inflammatory milieu that disrupts hematopoietic balance, favoring expansion of the myeloid lineage at the expense of lymphoid progenitors, which results in myeloid bias under chronic inflammatory stress [27]. This skewed hematopoiesis, combined with increased turnover of hematopoietic stem and progenitor cells, enhances the likelihood of acquiring somatic mutations relevant to clonal hematopoiesis and eventual leukemic evolution. The resulting bone marrow microenvironment is characterized by impaired stromal signaling and altered cytokine gradients that promote aberrant myelopoiesis and hinder normal hematopoietic differentiation [28]. Consequently, HIV-related immunosuppression significantly elevates malignancy risk, particularly for hematologic cancers. While Non-Hodgkin lymphoma (NHL) and Kaposi’s sarcoma remain the predominant HIV-associated neoplasms [29], emerging clinical evidence suggests an increased incidence of leukemias - particularly AML - likely mediated through these inflammatory and genotoxic mechanisms. People living with HIV (PLWH) exhibit significantly elevated risks of hematologic malignancies compared to immunocompetent individuals [30], attributable to multifactorial hematopoietic dysfunction involving both direct viral effects and secondary mechanisms. Although ART ameliorates some manifestations of cytopenia [31], the complex interactions between persistent HIV infection, ART-related toxicity, and the bone marrow microenvironment remain incompletely understood. Of particular clinical relevance is the observed increase in clonal hematopoiesis of indeterminate potential (CHIP) among PLWH - an aging-associated condition characterized by acquired somatic mutations that confers elevated risk for hematologic malignancies, particularly AML [13, 32, 33]. This accelerated CHIP phenotype suggests HIV infection may potentiate leukemogenic pathways through combined effects of chronic immune activation, recurrent antigenic stimulation, and prolonged exposure to inflammatory mediators, even in virologically suppressed individuals. On the other hand, during the early stages of HIV infection, the virus secretes the trans-activator (Tat) protein from infected CD4 + T cells into the bone marrow microenvironment. Tat plays a notable role in promoting angiogenesis, a process that may contribute to leukemogenesis. Additionally, Tat’s basic region can displace endogenous basic fibroblast growth factor (bFGF), a critical mediator of myelopoiesis, thereby impairing normal progenitor differentiation [13, 34]. These interactions collectively create an environment that may foster leukemic transformation. HIV-positive individuals with myelodysplastic syndromes (MDS) often present at a younger age and exhibit a higher frequency of mutations commonly associated with clonal hematopoiesis, particularly in genes such as ASXL1 and DNMT3A. Moreover, they tend to display cytogenetic profiles associated with poorer prognoses compared to HIV-negative individuals [13]. Exposure to specific environmental and pharmacologic agents further amplifies the leukemic risk in PLWH. These include cell cycle inhibitors, benzene derivatives, aliphatic hydrocarbons, cytotoxic drugs, and nucleoside analogues used in HIV treatment. Additionally, HIV-positive individuals may be particularly susceptible to ionizing radiation, which can exacerbate chromosomal instability through increased oxidative stress and impaired DNA repair. Radiation exposure may also induce mutations in key oncogenes such as c-myc and ras, both of which are pivotal in leukemic transformation. The synergistic impact of chronic inflammation, HIV infection, and ART further promotes genomic instability, thereby heightening the risk of radiation-induced leukemia in this population [35]. Moreover, infiltrative bone marrow disorders—whether neoplastic or infectious in origin—along with opportunistic infections, autoimmune mechanisms, nutritional deficiencies, and adverse effects of pharmacologic therapies, all contribute to the development of cytopenias in this patient group [31]. It is also well-documented that HIV infection and some ART regimens are associated with morphological changes in the bone marrow that mimic features of MDS, further complicating diagnosis and management [36]. Studies have shown that hematopoietic stem cells (HSCs) may serve as a viral reservoir in certain individuals, contributing to HIV latency and increasing HSC susceptibility to apoptosis [37]. Figure 1 depicts the molecular pathways and cellular mechanisms connecting HIV and AML pathogenesis. Molecular and cellular mechanisms linking HIV infection to acute myeloid leukemia (AML) pathogenesis. This schematic illustrates five interrelated pathways through which HIV infection may contribute to leukemogenesis: 1. Chronic inflammation driven by sustained elevation of pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) fosters a microenvironment conducive to malignant transformation. 2. Genomic instability induced by HIV accessory proteins (Tat, Nef) leads to DNA damage and mutagenesis in myeloid progenitor cells. 3. Oxidative stress resulting from HIV-associated reactive oxygen species (ROS) generation impairs hematopoietic stem cell (HSC) function and exacerbates DNA damage. 4. Bone marrow niche disruption occurs via HIV-mediated alterations in stromal cells and reduced cytokine support, undermining normal hematopoiesis. 5. Immune dysregulation marked by dysfunctional interactions among T cells, macrophages, and myeloid progenitors facilitates the expansion of malignant clones Impact of chemotherapy and art on hiv patients with AML The treatment of AML in individuals living with HIV presents unique clinical challenges. Management requires a delicate balance between effective leukemia control and sustained suppression of HIV replication. The coexistence of these two conditions compounds complications related to immunosuppression, potential drug toxicities, and pharmacological interactions between ART and chemotherapy. Although standard intensive chemotherapy protocols for AML have demonstrated comparable efficacy in both HIV-positive and HIV-negative populations, clinical outcomes in HIV-positive patients can vary significantly depending on factors such as CD4 + T-cell count, HIV viral load, and adherence to ART. Published case reports and clinical studies have shed light on therapeutic strategies, remission rates, and survival outcomes in this complex patient cohort, illustrating both progress made and persistent gaps in optimal care. For instance, one case report detailed a patient diagnosed concurrently with HIV and APL, who was successfully treated using a standard APL regimen consisting of all-trans retinoic acid (ATRA) and arsenic trioxide, alongside highly active antiretroviral therapy (HAART) for HIV management. This case underscored the feasibility and effectiveness of integrating conventional APL therapy with HAART, emphasizing the importance of maintaining viral suppression during leukemia treatment. It also highlighted the necessity for close monitoring to manage potential drug-drug interactions and overlapping toxicities [35]. In a case series involving 18 HIV-positive patients with AML, 15 of whom received standard antineoplastic chemotherapy, a complete response (CR) was achieved in 73% of patients—a rate comparable to outcomes observed in HIV-negative cohorts. These findings suggest that, in the absence of advanced AIDS and with preserved immune function (CD4 + T-cell count > 200 × 10⁶/L), standard cytotoxic regimens are both appropriate and effective for managing AML in HIV-positive individuals. Moreover, three patients in this cohort achieved durable remission, further supporting the viability of intensive chemotherapy in this setting [38]. Supporting this evidence, Dy et al. reported five new AML cases in HIV-positive patients and conducted a comprehensive review of 68 previously documented cases. Their multivariate analysis identified a strong association between achieving CR and prolonged survival, independent of CD4 + T-cell count. This reinforces the notion that HIV status alone should not preclude patients from receiving curative-intent AML therapy when appropriately supported [39]. Similarly, a French multicenter retrospective study demonstrated that intensive chemotherapy can be safely administered to HIV-positive patients with AML, provided care is delivered within a multidisciplinary framework. This study reported favorable outcomes in both efficacy and tolerability, highlighting the value of coordinated management involving oncologists, infectious disease specialists, and other healthcare professionals [40]. Taken together, these findings challenge the notion that HIV infection should automatically disqualify patients from receiving standard leukemia treatments [41]. The initiation or optimization of ART in oncology patients co-infected with HIV should be guided by an infectious disease specialist to ensure comprehensive care. The concurrent administration of ART and chemotherapy is now routine but poses significant challenges. These include inconsistent adherence, overlapping toxicities, suboptimal pharmacokinetics, and the potential for complex drug-drug interactions [42]. Nucleoside reverse transcriptase inhibitors (NRTIs) may interfere with transporter-mediated pharmacokinetics, while protease inhibitors, non-nucleoside reverse transcriptase inhibitors (NNRTIs), and CCR5 antagonists are primarily metabolized by the cytochrome P450 (CYP450) enzyme system and may modulate its activity through induction or inhibition. Despite these concerns, continuing ART during chemotherapy is generally recommended to promote immune reconstitution and minimize infection-related mortality. Among ART options, integrase strand transfer inhibitors (INSTIs)—such as raltegravir and dolutegravir—are favored due to their favorable safety profile, independence from pharmacokinetic boosters, and minimal interaction with CYP450-metabolized drugs. Moreover, many of the chemotherapeutic agents used in AML treatment, including anthracyclines and antimetabolites, are eliminated via non-CYP450 pathways, further reducing the likelihood of adverse pharmacologic interactions with ART [42–44]. Table 1 outlines the distinctive diagnostic, therapeutic, and prognostic considerations in HIV-positive patients with AML, as compared to their HIV-negative counterparts. These differences underscore the need for individualized care plans that account for immunological status, ART regimen, and potential drug interactions to optimize clinical outcomes. Table 1Comparative Analysis of Challenges in HIV-Positive and HIV-Negative AML PatientsAspectHIV-Positive AML PatientsHIV-Negative AML PatientsImmune StatusProfound immune suppression due to HIV infection; heightened risk of opportunistic infectionsImmunosuppression primarily due to AML or chemotherapy effects; less risk of opportunistic infectionsCytopeniasMultifactorial: caused by HIV, ART, and AML, complicating clinical interpretationDirectly linked to AML or chemotherapy-induced bone marrow suppressionDiagnosisDelayed due to overlapping symptoms (e.g., fever, cytopenias) with HIV-related conditionsSymptoms generally attributed to AML progression, leading to earlier diagnosisTherapeutic ChallengesComplex drug-drug interactions between ART and chemotherapy; increased overlapping toxicities (e.g., hepatotoxicity, cytopenias)Standard chemotherapy toxicities such as neutropenia and gastrointestinal side effectsPrognosisPoorer due to dual disease burden, increased infection risk, and limited therapeutic optionsPrognosis primarily depends on AML subtype and response to treatmentSpecial ConsiderationsImmune reconstitution inflammatory syndrome (IRIS) during ART; requires careful management of ART timing and dosage adjustmentsRisk of chemotherapy-induced complications, including prolonged neutropenia, febrile episodes, and sepsis Comparative Analysis of Challenges in HIV-Positive and HIV-Negative AML Patients Clinical manifestations, diagnosis, and prognosis of AML in HIV-positive patients The clinical presentation of AML frequently overlaps with that of HIV infection, posing significant challenges for early diagnosis. Common symptoms—such as fatigue, recurrent infections, and unintended weight loss—are characteristic of both conditions, often leading to misdiagnosis or delayed recognition of AML in individuals living with HIV. Hematologic abnormalities like anemia, leukopenia, and thrombocytopenia, which are hallmark features of AML, also occur commonly in HIV-positive patients. These may arise either from direct viral effects on bone marrow or as consequences of ART and opportunistic infections [45, 46]. Hence, clinicians should maintain a high index of suspicion for AML in HIV-infected patients presenting with persistent or unexplained cytopenias, particularly when these abnormalities do not resolve with optimized ART or effective management of infections. HIV-related immunosuppression can significantly alter typical immune responses, thereby obscuring classical signs of AML. In immunocompetent individuals, AML often manifests with neutropenic fever, bleeding diatheses, or bone pain [46]. However, in the context of HIV, these symptoms may be muted or atypical due to impaired immune function, potentially delaying appropriate investigation and diagnosis [8]. Furthermore, opportunistic infections—common in advanced HIV—may mimic or exacerbate AML-like features, compounding diagnostic complexity. Consequently, a comprehensive diagnostic approach is essential, involving detailed clinical evaluation, complete blood count analyses, and bone marrow examination when cytopenias persist despite adequate ART and infection control efforts. The use of specific biomarkers and diagnostic tools can aid in distinguishing AML from HIV-associated hematologic changes. Immunophenotypic markers such as CD34 and CD117, which are indicative of myeloid progenitor cells, can help differentiate leukemic blasts from reactive bone marrow processes frequently seen in HIV-positive patients [47]. Additionally, molecular testing for mutations commonly associated with AML—such as FLT3-ITD, NPM1, and DNMT3A—can provide diagnostic clarity when conventional hematologic parameters are inconclusive [48]. Advanced diagnostic modalities, including positron emission tomography (PET) imaging and cytogenetic analysis, may further assist in assessing disease extent and differentiating AML from other causes of cytopenia in this patient population [49]. Prognosis The prognosis of AML in individuals living with HIV is influenced by a complex interplay of factors, including viral load, CD4 + T-cell counts, and response to both antiretroviral and leukemia-directed therapies. While some studies have suggested that higher CD4 + counts are associated with improved performance status—likely reflecting better immune reconstitution and a reduced susceptibility to infections—other research indicates that achieving complete remission through standard AML treatment may offset the prognostic impact of baseline CD4 + levels [8]. This apparent discrepancy highlights the multifactorial nature of outcomes in this patient population, where effective control of leukemia, sustained viral suppression, and comprehensive supportive care all contribute meaningfully to survival. A nuanced understanding of these interdependencies is essential for tailoring therapeutic strategies to the individual clinical profile of each patient. Future directions and research gaps The relationship between HIV and AML presents a compelling and underexplored avenue for research. To deepen our understanding of this intersection, large, longitudinal cohort studies encompassing diverse stages of HIV infection and varying host characteristics are critically needed. Such studies would be instrumental in elucidating the long-term risk of AML, the role of chronic immune activation, and the effects of ART on hematopoiesis. Equally important is the investigation of molecular pathways that may link HIV infection to leukemogenesis. Mechanisms involving chronic inflammation, oxidative stress, and the interaction between HIV proteins and host cellular signaling pathways warrant comprehensive examination. Emerging evidence suggests that ART-related hematologic toxicity may play a dual role—potentially contributing to leukemogenesis while simultaneously offering protection by suppressing viral replication and reducing systemic inflammation. These dynamics merit further exploration. In addition, novel immunotherapeutic strategies such as chimeric antigen receptor (CAR) T-cell therapy and immune checkpoint inhibitors represent promising avenues for AML treatment. However, their safety, efficacy, and immunological impact in HIV-positive individuals remain inadequately characterized. More established approaches, such as allogeneic hematopoietic cell transplantation (allo-HCT), have demonstrated greater efficacy in AML compared to CAR-T and checkpoint inhibitors, particularly in achieving durable remission. In HIV-positive patients, allo-HCT has been performed with careful conditioning and immune monitoring [50]. Notably, transplantation from donors homozygous for the CCR5Δ32 mutation—conferring resistance to HIV—has led to sustained HIV remission in some cases [51–53]. These findings highlight the dual therapeutic potential of allo-HCT in treating both AML and HIV, warranting further investigation into donor selection and transplant protocols. Tailoring these therapies to the unique immunologic profiles of PLWH will be essential for their safe and effective integration into care. Despite these promising directions, critical gaps in knowledge persist. PLWH remain significantly underrepresented in AML clinical trials, resulting in limited data on disease-specific treatment outcomes within this group. Furthermore, population-level data on the incidence and prevalence of AML in HIV-positive individuals remain sparse, particularly in low-resource settings, where underdiagnosis of both conditions is common. The identification of specific biomarkers for AML in the context of HIV could enable earlier detection and support differential diagnosis from other HIV-related hematologic disorders. Finally, research into survivorship and quality of life among individuals with both AML and HIV is notably lacking. A deeper understanding of these dimensions could yield valuable insights into the long-term impact of AML and its treatment in this vulnerable population, ultimately guiding the development of patient-centered strategies to improve clinical outcomes and quality of life. Conclusion The co-occurrence of HIV and AML presents a distinct and complex clinical challenge, both for affected individuals and for the healthcare systems tasked with managing their care. Although the precise incidence of AML among HIV-positive individuals remains uncertain, existing evidence points to an increased susceptibility. Advances in HIV treatment have markedly improved life expectancy, shifting attention toward non-AIDS-defining malignancies such as AML, which are emerging as significant comorbid concerns in this population. Despite these shifts, substantial research gaps persist—particularly in our understanding of the molecular mechanisms linking HIV to leukemogenesis, the safety and efficacy of novel therapeutic approaches, and the persistent diagnostic challenges in low-resource settings. Addressing these gaps requires a concerted interdisciplinary research effort and the design of inclusive clinical trials that adequately represent HIV-positive populations. Bridging these knowledge gaps is critical not only for advancing our understanding of the biological interplay between HIV and AML but also for enabling earlier diagnosis and the development of more precise, personalized treatment strategies. Ultimately, such progress will be key to improving both clinical outcomes and the overall quality of life for patients navigating the complexities of this dual diagnosis. Acknowledgements None. Author contributions M.J.S. and F.A.M. conceived the study and designed the methodology; F.A.M., R.J.A., and S.G. conducted the literature review and data curation; A.S., A.S., and M.J.J. performed formal analysis; M.J.S., F.A.M., and V.A. wrote the original draft; all authors critically reviewed and edited the manuscript; R.J.A. and A.M.A.A. prepared the figure and table; F.A.M. and J.R. supervised the project; W.M.T. and M.A. managed project administration. Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Data availability Not applicable. Declarations Competing interests The authors declare no competing interests. Ethics approval Not applicable. Consent to participate Not applicable. Consent to publish Not applicable. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement Not applicable.